Uniqure N.V. (QURE)

$14.05 -0.16 (-1.13%)
Market Cap 692.64M
Revenue (ttm) 15.84M
Net Income (ttm) -308.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,947.47%
Debt to Equity Ratio 0.92
Volume 994,500
Avg Vol 2,553,740
Day's Range N/A - N/A
Shares Out 48.74M
Stochastic %K 16%
Beta 0.41
Analysts Strong Sell
Price Target $30.91

Latest News on QURE

uniQure Announces Pricing of its Public Offering

Jan 8, 2025, 7:05 AM EST - 9 days ago

uniQure Announces Pricing of its Public Offering

uniQure Announces Proposed Public Offering

Jan 7, 2025, 4:49 PM EST - 10 days ago

uniQure Announces Proposed Public Offering

Final Trade: DVN, QURE, GOOGL, DFH

Dec 30, 2024, 6:31 PM EST - 18 days ago

Final Trade: DVN, QURE, GOOGL, DFH

GOOG GOOGL DFH DVN

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

Dec 10, 2024, 7:05 AM EST - 5 weeks ago

uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Nov 21, 2024, 7:05 AM EST - 2 months ago

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Nov 5, 2024, 7:05 AM EST - 2 months ago

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

Oct 15, 2024, 7:05 AM EDT - 3 months ago

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

Sep 23, 2024, 7:05 AM EDT - 4 months ago

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

Aug 15, 2024, 7:05 AM EDT - 5 months ago

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

Aug 6, 2024, 3:03 AM EDT - 5 months ago

uniQure: Pullback After Strong Interim Treatment Data Creates Buying Opportunity

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

Aug 1, 2024, 7:05 AM EDT - 6 months ago

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

Jul 23, 2024, 7:05 AM EDT - 6 months ago

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

What Led To A 150% Rise In UniQure Stock In A Week?

Jul 12, 2024, 8:00 AM EDT - 6 months ago

What Led To A 150% Rise In UniQure Stock In A Week?

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

Jul 9, 2024, 1:48 PM EDT - 6 months ago

uniQure: Positive HD AMT-130 Treatment Data Leads To Several Other Catalysts

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

Jul 9, 2024, 7:05 AM EDT - 6 months ago

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Jul 1, 2024, 7:05 AM EDT - 7 months ago

uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

Jul 1, 2024, 7:05 AM EDT - 7 months ago

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

Jun 3, 2024, 7:05 AM EDT - 8 months ago

uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's Disease

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

May 7, 2024, 7:05 AM EDT - 9 months ago

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

Feb 28, 2024, 7:05 AM EST - 11 months ago

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

uniQure: The Valuation Got More Attractive

Feb 1, 2024, 2:25 PM EST - 1 year ago

uniQure: The Valuation Got More Attractive

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

Dec 19, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Dec 11, 2023, 7:30 PM EST - 1 year ago

CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 8, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

Nov 29, 2023, 7:05 AM EST - 1 year ago

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Nov 7, 2023, 7:05 AM EST - 1 year ago

uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

CSL and uniQure Win 2023 Prix Galien USA Award

Oct 27, 2023, 10:00 AM EDT - 1 year ago

CSL and uniQure Win 2023 Prix Galien USA Award

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

Oct 24, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

Oct 5, 2023, 8:18 AM EDT - 1 year ago

UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

Gene therapy maker UniQure to cut about 20% of workforce

Oct 5, 2023, 7:21 AM EDT - 1 year ago

Gene therapy maker UniQure to cut about 20% of workforce

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

Oct 5, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

Sep 5, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

Aug 1, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

Jun 26, 2023, 7:11 AM EDT - 1 year ago

uniQure Announces Leadership Addition to Support Advancement of Clinical Programs

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm

Jun 22, 2023, 8:45 AM EDT - 1 year ago

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against uniQure N.V. and Encourages Investors with Losses to Contact the Firm

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

Jun 21, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington's Disease

uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy

Jun 20, 2023, 7:05 AM EDT - 1 year ago

uniQure announces achievement of $100 million milestone related to hemophilia B gene therapy

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B

Jun 20, 2023, 7:00 AM EDT - 1 year ago

CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B

Market Is Still Not Pricing In The FDA And EU EMA Approvals For uniQure

May 22, 2023, 5:38 PM EDT - 1 year ago

Market Is Still Not Pricing In The FDA And EU EMA Approvals For uniQure

uniQure: Financials And Pipeline Signal A Promising Outlook For Investors

May 20, 2023, 9:19 AM EDT - 1 year ago

uniQure: Financials And Pipeline Signal A Promising Outlook For Investors

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

May 15, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces Sale of Royalty Interest in HEMGENIX® for Up To $400 Million

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 9, 2023, 7:05 AM EDT - 1 year ago

uniQure Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 2, 2023, 4:40 PM EDT - 1 year ago

uniQure Announces Major Presence at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

uniQure to Participate in Multiple Upcoming Industry Conferences in March

Mar 2, 2023, 7:05 AM EST - 2 years ago

uniQure to Participate in Multiple Upcoming Industry Conferences in March

uniQure Announces 2022 Financial Results and Highlights Recent Company Progress

Feb 27, 2023, 7:05 AM EST - 2 years ago

uniQure Announces 2022 Financial Results and Highlights Recent Company Progress

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

Feb 23, 2023, 8:05 AM EST - 2 years ago

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)

Feb 23, 2023, 8:00 AM EST - 2 years ago

CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)